Comparative Study of Two Processes to Improve the Bioavailability of an Active Pharmaceutical Ingredient: Kneading and Supercritical Technology

Autor: Jacques Fages, Elisabeth Rodier, Alain Chamayou, Michel Baron

Publikováno v: KONA Powder and Particle Journal, Vol 25, Iss 0, Pp 217-229 (2014)

Two processes have been developed for the enhancement of bioavailability of a poorly-soluble active substance, Eflucimibe by associating it with γ-CD (γ-cyclodextrin).In the first process (process a), Eflucimibe was added to an aqueous slurry of CD

Externí odkaz: https://doaj.org/article/89a36a49ca994338add94704e90b6b21

Nucleation Kinetics of Polymorphs: Induction Period and Interfacial Energy Measurements

Autor: Sébastien Teychené, Béatrice Biscans

Publikováno v: Crystal Growth & Design. 8:1133-1139

Nucleation kinetics of eflucimibe polymorphs have been investigated in ethanol and n-heptane mixture. The two eflucimibe polymorphs, A and B, crystallize concomitantly for a wide range of operating conditions. The effects of supersaturation on the nu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7701872ca0238c726656eaf1ae8577a
https://doi.org/10.1021/cg0609320

Spectrofluorimetric study of eflucimibe-γ-cyclodextrin inclusion complex

Autor: Nathalie Mesplet, Philippe Morin, Jean-Paul Ribet

Publikováno v: European Journal of Pharmaceutics and Biopharmaceutics. 59:523-526

Eflucimibe, a novel and highly potent acyl-coenzyme A cholesterol O-acyl-transferase (ACAT) inhibitor, is sparingly soluble in aqueous media and exhibits a very weak natural fluorescence. However, when increasing concentrations of gamma-cyclodextrin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a7c14253b4b3f488e764d384932e480
https://doi.org/10.1016/j.ejpb.2004.09.011

Evolution of the interaction of a new chemical entity, eflucimibe, with γ-cyclodextrin during kneading process

Autor: E. Leverd, J. Bougaret, Alain Chamayou, Guy Couarraze, A. Gil, Michel Baron

Publikováno v: Scopus-Elsevier
European Journal of Pharmaceutical Sciences
European Journal of Pharmaceutical Sciences, Elsevier, 2004, 23 (2), p.123-129. ⟨10.1016/j.ejps.2004.06.002⟩

International audience; The aim of this study was to enhance the low solubility of eflucimibe, a new chemical entity which can be used as medicine to treat dyslipidemiae, by complexation with gamma-cyclodextrin. The complex was prepared using kneadin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf22583a4450e78744872112985aa83
https://doi.org/10.1016/j.ejps.2004.06.002

Analysis of eflucimibe and related impurities by highly sensitive liquid chromatography-electrospray-tandem mass spectrometry

Autor: Philippe Morin, Jean-Paul Ribet, Nathalie Mesplet

Publikováno v: Journal of Separation Science. 26:1353-1358

Eflucimibe (F 12511) is a new and promising acyl-coenzyme A cholesterol O-acyltransferase (ACAT) inhibitor, developed at the Pierre Fabre Research Center for the treatment of atherosclerosis. Owing to the synthetic pathway, residual impurities may be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f36fc0355048f8a76938503345d1e048
https://doi.org/10.1002/jssc.200301551